Gene therapy biotech Ray Therapeutics has announced the closing of a $125 million series B financing to support the company’s vision restoration candidates for patients with retinal degeneration.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Gene therapy biotech Ray Therapeutics has announced the closing of a $125 million series B financing to support the company’s vision restoration candidates for patients with retinal degeneration.